Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
In an attempt to prospectively validate the existence of supersensitivity psychosis (SSP), five schizophrenic patients meeting Chouinard's criteria for SSP and five non-SSP schizophrenic controls had neuroleptic treatment withdrawn for 2 weeks under double-blind conditions. The sudden worsening of psychotic symptoms and tardive dyskinesia postulated in the SSP group was not observed on the Brief Psychiatric Rating Scale, the Clinical Global Impressions scale, and the Abbreviated Dyskinesia Rating Scale. In conclusion, the authors' pilot data do not seem to support the existence of SSP.
Singh
H
H
Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129.
Hunt
J I
JI
Vitiello
B
B
Simpson
G M
GM
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000139:chemically induced* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013375:Substance Withdrawal Syndrome / Q000209:etiology* / Q000523:psychology
D014150:Antipsychotic Agents; D010919:Placebos